Keenova Announces Two New TERLIVAZ® (terlipressin) Analyses at The Liver Meeting®

Barchart · 2d ago

DUBLIN, Nov. 5, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that two new presentations highlighting clinical trial and real-world evidence related to TERLIVAZ® (terlipressin) in treating hepatorenal syndrome-acute kidney injury (HRS-AKI) will be presented at The Liver Meeting®, the annual conference of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-8, 2026.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.